Table 1 Baseline clinical characteristics of the study cohort and best response to combination therapy
Characteristics | Total, No. (%) |
|---|---|
No. of patients | 30 |
Age, years | |
 Median | 56 |
 Range | 48–69 |
Sex | |
 Male | 22 (73.4) |
 Female | 8 (26.6) |
Smoking history | |
 Never smoker | 14 (46.7) |
 Former smoker | 16 (53.3) |
Histology | |
 Adenocarcinoma | 16 (53.3) |
 Squamous carcinoma | 14 (46.7) |
Eastern Cooperative Oncology Group performance status | |
 0–1 | 30 (100) |
  ≥ 2 | 0 |
Brain metastasis | |
 Yes | 1 (3.3) |
 No | 29 (96.7) |
Stage | |
 IIIa/IIIb | 4 (13.4) |
 IV | 26 (86.6) |
Best response with sintilimab plus docetaxel | |
 Complete Response | 0 |
 Partial Response | 11 (36.7) |
 Stable Disease | 13 (43.3) |
 Progressive Disease | 6 (20) |
 Objective Response Rate | 36.7% |